




Antiviral drugs


Prepared by

Assistant professor/ HEBA AHMED HASSAN
Clinical pharmacology department
Faculty of medicine – MUTAH University
(2025-2024)

Virus structures



Steps of virus replication



1. BINDING TO CELL SURFACE RECEPTORS

HOST CELL

3. UNCOATING

Rev. transcriptase

RNA polymerase

4. REPLICATION

RNA viruses

viral RNA

8. RELEASE

Neuraminidase

DNA viruses

DNA polymerase


Integrase

6. TRANSLATION

7. VIRION ASSEMBLY

5. TRANSCRIPTION

mRNA



```
graph TD; A[Antiviral drugs] --- B[Anti-herpetic drugs]; A --- C[Anti-influenzal drugs]; A --- D[Anti-HIV drugs]; E((Anti-hepatitis drugs))
```

Antiviral drugs

Anti-
hepatitis
drugs

**Anti-herpetic
drugs**

**Anti-influenzal
drugs**

Anti-HIV drugs

-Anti-herpetic drugs (DNA VIRUS)

1–Acyclovir, famciclovir, valacyclovir

2–Ganciclovir, Valganciclovir


3–Foscarnet



1-Acyclovir- famciclovir- valacyclovir

Activation Guanosine analogs


- ▶ Mono-phosphorylated by HSV/VZV thymidine kinase (TK) (not phosphorylated in uninfected cells → few adverse effects).
- ▶ They are further activated by host-cell kinases to the triphosphates




Mechanism of action

- Triphosphates are substrates for viral **DNA polymerase** → incorporated into the DNA molecule → **chain terminations**

Mechanism of Action of Acyclovir



(b) The enzyme thymidine kinase combines phosphates with nucleosides to form nucleotides, which are then incorporated into DNA.



(c) Acyclovir has no effect on a cell not infected by a virus, that is, with normal thymidine kinase. In a virally infected cell, the thymidine kinase is altered and converts the acyclovir (which resembles the nucleoside deoxyguanosine) into a false nucleotide—which blocks DNA synthesis by DNA polymerase.


▶ Clinical uses:

- ✓ Treatment of herpes simplex and varicella zoster virus infections
- ✓ Prophylaxis in immuno-compromized patients

▶ Toxicity

- ✓ Crystalluria & nephropathy so Maintain good hydration

Notes

- ❖ No role in post-herpetic neuralgia
 - ❖ Valacyclovir is a prodrug of acyclovir (oral=IV acyclovir)
 - ❖ For herpes zoster, use famciclovir
- 

2-Ganciclovir

Activation: Monophosphorylated by CMV kinase → effective against CMV.

Mechanism of action: Like acyclovir.

Clinical uses:

- ✓ Treatment & prophylaxis of **cytomegalic virus infection** (especially immunocompromized patients).

Toxicity:

- Myelo-suppression (Leucopenia, thrombocytopenia).
- Nephropathy


Notes:

- ❖ **Valganciclovir** is a prodrug with **better bioavailability** (oral replacement for IV ganciclovir)

3-Foscarnet

- ✓ Doesn't require activation by viral or human kinases
- ▶ **Mechanism of action:**
 - ✓ Inhibition(-) of Viral DNA polymerase
 - ✓ (-) RNA polymerase
 - ✓ (-) HIV reverse transcriptase
- ▶ **Clinical uses:**
 - ✓ Ganciclovir-resistant **CMV infection**
 - ✓ Acyclovir-resistant **HSV infection**
- ▶ **Toxicity:**
 - ✓ Nephrotoxicity
 - ✓ Electrolyte disturbances that may cause seizures (hypocalcemia & hypomagnesemia)

NNRTIs $\xrightarrow{\ominus}$ DNA Polymerase (DNA- or RNA-directed)
Foscarnet



Common Mechanism for “ovirs” and NRTIs

Anti influenza (RNA VIRAL)

Amantadine & rimantadine

Oseltamivir & Zanamivir

1-Amantadine & Rimantadine

▶ **Mechanism of action:**

- ✓ Block attachment, penetration, and uncoating of influenza A virus

▶ **Clinical uses:**

- ❖ Influenza prophylaxis (no longer useful due to high resistance).
- ❖ Adjuvant anti-parkinsonian effect (with rapid tolerance).

▶ **Toxicity:**

- ✓ Nervousness, Insomnia, Seizures with overdose and Atropine-like action

2-Oseltamivir & Zanamivir

▶ Mechanism of action:

inhibit neuraminidases of influenza A & B → viral clumping → prevents new viral particles from being released in the body.

▶ Clinical uses:

- ❖ Prevention & treatment of influenza A & B




Anti-HIV drugs

Fusion inhibitors

Reverse transcriptase inhibitors (NRTIs).

Protease inhibitors (PIs).

Integrase inhibitors



- ▶ Highly active antiretroviral therapy (**HAART**) is often initiated on the time of diagnosis.
- ▶ Strongest indication is for patients with AIDS-defining illness, **low CD4+** (< 500 cells/mm³), or **high viral load**.
- ▶ **Regimen** consists of **3 drugs** (to prevent resistance):
 - _ 2 NRTIs and 1 of the following (NNRTIs, protease inhibitors, or integrase inhibitors).

Nucleoside reverse transcriptase inhibitors (NRTIs):

- ▶ 1- Zidovudine. 2- Lamivudine.
- ▶ 3- Tenofovir 4- Didanosine

Mechanism of action:

- ▶ Phosphorylated by host kinases (except tenofovir).
- ▶ Cause competitive inhibition of reverse transcriptase and chain termination of DNA.

Clinical use:

Main component of HAART.

Zidovudine

Is used for general prophylaxis and for prevention of vertical transmission in pregnancy.

Toxicity:

- *Bone marrow depression (can be reversed by granulocyte colony stimulating factor [G-CSF] and erythropoietin).*
- *Peripheral neuropathy and myopathy.*
- *Lactic acidosis.*

Non-nucleoside reverse transcriptase inhibitors (NNRTIs).

▶ *Efavirenz, Etravirin.*

▶ **Mechanism:**

- Bind to and inhibit reverse transcriptase inhibiting DNA synthesis.
- No need for phosphorylation
- Not competitive (bind to a site other than site of NRTIs).

▶ **Toxicity:**

- Rash & hepatotoxicity (common with all members).
- Efavirenz causes vivid dreams and is contraindicated with pregnancy.

Protease inhibitors (PIs).

▶ Atazanavir, Lopinavir, Ritonavir.

▶ Mechanism :

- HIV-1 **protease** cleaves the polypeptide products of the viral mRNA into functional parts, which then allow the assembly and maturation of new viruses.
- PIs act by ***inhibiting*** this enzyme.
- ***Ritonavir*** is usually combined with other PIs, increasing their activity by inhibiting CYP450.

► Toxicity:

- Hyperglycemia (insulin resistance) & lipodystrophy.
- Nausea & diarrhea.
- Drug-drug interactions.

N.B. No bone marrow depression.

Integrase inhibitors.

► **Raltegravir** and **Elvitegravir**

► ***Mechanism :***

Inhibit **integration** of viral genome in host cell DNA.

1- Fusion inhibitors: Enfuvirtide AND Maraviroc

Enfuvirtide

⊗ Mechanism of action:

- It binds to the gp41 subunit of the viral envelope glycoprotein, preventing the fusion of the viral and cellular membranes.

▶ Adverse effects:

1. Injection site reaction and hypersensitivity.
2. Increased incidence of bacterial pneumonia

Maraviroc


⊗ Mechanism of action:

- binds specifically and selectively to the membrane host protein CCR5, one of two chemokine receptors necessary for entry of HIV into CD4+ cells

- ▶ So, it inhibits binding and entry of the virus into immune cells

▶ Adverse effects:

- ▶ 1- Cough
- ▶ 2-Diarrhea
- ▶ 3-Muscle and joint pain



Enfuvirtide




gp41



gp120



Maraviroc





**Thank
You!!!**

www.thebodytransformation.com